No retraction, correction or concern found when last checked on Oct 20, 2026.

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic

Tirosh Shapira, I. Abrrey Monreal, Sébastien P. Dion and 23 more (opens in a new tab)

Nature · 2022 · CC BY

doi:10.1038/s41586-022-04661-w (opens in a new tab)

Abstract

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern 1,2 . Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against variants of concern 3,4 . Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs) such as TMPRSS2; these proteases cleave the viral spike protein to expose the fusion peptide for cell entry, and thus have an essential role in the virus lifecycle 5,6 . Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a selectivity index of higher than 10 6 in inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids 7 . In Calu-3 cells it inhibits the entry of the SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta). Notably, in the K18-human ACE2 transgenic mouse model of severe COVID-19, we found that N-0385 affords a high level of prophylactic and therapeutic benefit after multiple administrations or even after a single administration. Together, our findings show that TTSP-mediated proteolytic maturation of the spike protein is critical for SARS-CoV-2 infection in vivo, and suggest that N-0385 provides an effective early treatment option against COVID-19 and emerging SARS-CoV-2 variants of concern.

References 67

1.
Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602:671-675.
Not in our library10.1038/s41586-021-04389-z (opens in a new tab)
2.
Tao K, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 2021;22:757-773.
Not in our library10.1038/s41576-021-00408-x (opens in a new tab)
3.
Cell entry mechanisms of SARS-CoV-2 · 2020
No notice
4.
Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.
Not in our library10.1016/j.cell.2020.02.052 (opens in a new tab)
5.
Wong JP, Damania B. SARS-CoV-2 dependence on host pathways. Science. 2021;371:884-885.
Not in our library10.1126/science.abg6837 (opens in a new tab)
6.
Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3-20.
Not in our library10.1038/s41580-021-00418-x (opens in a new tab)
7.
Rees WD, et al. Enteroids derived from inflammatory bowel disease patients display dysregulated endoplasmic reticulum stress pathways, leading to differential inflammatory responses and dendritic cell maturation. J. Crohns Colitis. 2020;14:948-961.
Not in our library10.1093/ecco-jcc/jjz194 (opens in a new tab)
8.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
9.
COVID-19 Dashboard. Center for Systems Science and Engineering (CSSE) at Johns Hopkins Universityhttps://coronavirus.jhu.edu/map.html.
Not in our library10.1016/s1473-3099(22)00434-0 (opens in a new tab)
10.
Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021;600:204-207.
Not in our library10.1038/d41586-021-03619-8 (opens in a new tab)
11.
Plante JA, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29:508-515.
Not in our library10.1016/j.chom.2021.02.020 (opens in a new tab)
12.
Sievers BL, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 2022;14:eabn7842.
Not in our library10.1126/scitranslmed.abn7842 (opens in a new tab)
13.
Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J. Transl. Med. 2020;18:390.
Not in our library10.1186/s12967-020-02476-9 (opens in a new tab)
14.
SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development · 2021
No notice
15.
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir · 2021
No notice
16.
Beigel JH, et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 2020;383:1813-1826.
Not in our library10.1056/nejmoa2007764 (opens in a new tab)
17.
Owen DR, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586-1593.
Not in our library10.1126/science.abl4784 (opens in a new tab)
18.
Wahl A, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451-457.
Not in our library10.1038/s41586-021-03312-w (opens in a new tab)
19.
Gunst JD, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. eClinicalMedicine. 2021;35:100849.
Not in our library10.1016/j.eclinm.2021.100849 (opens in a new tab)
20.
Beumer J, et al. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat. Commun. 2021;12:5498.
Not in our library10.1038/s41467-021-25729-7 (opens in a new tab)
21.
Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78:779-784.
Not in our library10.1016/j.molcel.2020.04.022 (opens in a new tab)
22.
Tang T, et al. Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin. ACS Infect. Dis. 2021;7:264-272.
Not in our library10.1021/acsinfecdis.0c00701 (opens in a new tab)
23.
Hoffmann M, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. eBioMedicine. 2021;65:103255.
Not in our library10.1016/j.ebiom.2021.103255 (opens in a new tab)
24.
Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection · 2020
No notice
25.
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A · 2021
No notice
26.
Dampalla, C. S. et al. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc. Natl Acad. Sci. USA 118, e2101555118 (2021).
Not in our library10.1073/pnas.2101555118 (opens in a new tab)
27.
Colombo É, et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med. Chem. Lett. 2012;3:530-534.
Not in our library10.1021/ml3000534 (opens in a new tab)
28.
Beaulieu A, et al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J. Virol. 2013;87:4237-4251.
Not in our library10.1128/jvi.03005-12 (opens in a new tab)
29.
St-Georges C, et al. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. Eur. J. Med. Chem. 2017;129:110-123.
Not in our library10.1016/j.ejmech.2017.02.006 (opens in a new tab)
30.
Murza A, et al. Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract–a review of patent literature. Expert Opin. Ther. Pat. 2020;30:807-824.
Not in our library10.1080/13543776.2020.1817390 (opens in a new tab)
31.
Shrimp JH, et al. An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19. ACS Pharmacol. Transl. Sci. 2020;3:997-1007.
Not in our library10.1021/acsptsci.0c00106 (opens in a new tab)
32.
Béliveau F, et al. Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chem. Biol. 2019;26:1559-1572.
Not in our library10.1016/j.chembiol.2019.09.004 (opens in a new tab)
33.
Long RKM, et al. Super resolution microscopy and deep learning identify Zika virus reorganization of the endoplasmic reticulum. Sci. Rep. 2020;10:20937.
Not in our library10.1038/s41598-020-77170-3 (opens in a new tab)
34.
Staab JF, Lemme-Dumit JM, Latanich R, Pasetti MF, Zachos NC. Co-culture system of human enteroids/colonoids with innate immune cells. Curr. Protoc. Immunol. 2020;131:e113.
Not in our library10.1002/cpim.113 (opens in a new tab)
35.
SARS-CoV-2 productively infects human gut enterocytes · 2020
No notice
36.
Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327-1335.
Not in our library10.1038/s41590-020-0778-2 (opens in a new tab)
37.
McCray PB, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813-821.
Not in our library10.1128/jvi.02012-06 (opens in a new tab)
38.
Johansen MD, et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 2020;13:877-891.
Not in our library10.1038/s41385-020-00340-z (opens in a new tab)
39.
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model · 2021
Not checked
40.
Laporte M, Naesens L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr. Opin. Virol. 2017;24:16-24.
Not in our library10.1016/j.coviro.2017.03.018 (opens in a new tab)
41.
Klingenstein M, et al. Evidence of SARS-CoV2 entry protein ACE2 in the human nose and olfactory bulb. Cells Tissues Organs. 2020;209:155-164.
Not in our library10.1159/000513040 (opens in a new tab)
42.
SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells · 2020
No notice
43.
Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice · 2013
Corrected
44.
Mahoney M, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc. Natl Acad. Sci. 2021;118:e2108728118.
Not in our library10.1073/pnas.2108728118 (opens in a new tab)
45.
Lutz C, Maher L, Lee C, Kang W. COVID-19 preclinical models: Human angiotensin-converting enzyme 2 transgenic mice. Hum. Genomics. 2020;14:20.
Not in our library10.1186/s40246-020-00272-6 (opens in a new tab)
46.
Soldatov VO, Kubekina MV, Silaeva YY, Bruter AV, Deykin AV. On the way from SARS-CoV-sensitive mice to murine COVID-19 model. Res. Results Pharmacol. 2020;6:1-7.
Not in our library10.3897/rrpharmacology.6.53633 (opens in a new tab)
47.
TS H, et al. Intranasal antiviral drug delivery and coronavirus disease 2019 (COVID-19): a state of the art review. Otolaryngol. Head Neck Surg. 2020;163:682-694.
Not in our library10.1177/0194599820933170 (opens in a new tab)
48.
Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021;14:305-316.
Not in our library10.1038/s41385-020-00359-2 (opens in a new tab)
49.
Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018;143:155-170.
Not in our library10.1016/j.brainresbull.2018.10.009 (opens in a new tab)
50.
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets · 2021
No notice
51.
Sun YJ, et al. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice. J. Clin. Invest. 2021;131:e147973.
Not in our library10.1172/jci147973 (opens in a new tab)
52.
Shen BQ, Finkbeiner WE, Wine JJ, Mrsny RJ, Widdicombe JH. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl− secretion. Am. J. Physiol. 1994;266:L493-L501.
Not in our library10.1152/ajplung.1994.266.5.l493 (opens in a new tab)
53.
Variability in docking success rates due to dataset preparation · 2012
No notice
54.
SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology · 2020
No notice
55.
Shapira T, et al. High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against Mycobacterium tuberculosis. Front. Microbiol. 2020;11:553962.
Not in our library10.3389/fmicb.2020.553962 (opens in a new tab)
56.
Olmstead AD, Knecht W, Lazarov I, Dixit SB, Jean F. Human subtilase SKI-1/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS Pathog. 2012;8:e1002468.
Not in our library10.1371/journal.ppat.1002468 (opens in a new tab)
57.
Désilets A, Longpré JM, Beaulieu MÈ, Leduc R. Inhibition of human matriptase by eglin c variants. FEBS Lett. 2006;580:2227-2232.
Not in our library10.1016/j.febslet.2006.03.030 (opens in a new tab)
58.
Béliveau F, Désilets A, Leduc R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS J. 2009;276:2213-2226.
Not in our library10.1111/j.1742-4658.2009.06950.x (opens in a new tab)
59.
Brosseau J-P, et al. High-throughput quantification of splicing isoforms. RNA. 2010;16:442-449.
Not in our library10.1261/rna.1877010 (opens in a new tab)
60.
qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data · 2007
No notice
61.
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice · 2020
No notice
62.
Zheng J, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589:603-607.
Not in our library10.1038/s41586-020-2943-z (opens in a new tab)
63.
Burkholder T, Foltz C, Karlsson E, Linton CG, Smith JM. Health evaluation of experimental laboratory mice. Curr. Protoc. Mouse Biol. 2012;2:145-165.
Not in our library10.1002/9780470942390.mo110217 (opens in a new tab)
64.
Meyerholz DK, Beck AP. Histopathologic evaluation and scoring of viral lung infection. Methods Mol. Biol. 2020;2099:205-220.
Not in our library10.1007/978-1-0716-0211-9_16 (opens in a new tab)
65.
Achanta R, et al. SLIC superpixels compared to state-of-the-art superpixel methods. IEEE Trans. Pattern Anal. Mach. Intell. 2012;34:2274-2281.
Not in our library10.1109/tpami.2012.120 (opens in a new tab)
66.
QuPath: Open source software for digital pathology image analysis · 2017
No notice
67.
Sarret P. Éric Marsault (1971–2021): a legacy through the prism of relationship chemistry. J. Med. Chem. 2021;64:5221-5224.
Not in our library10.1021/acs.jmedchem.1c00481 (opens in a new tab)

Cited by papers we hold 1

An intranasal ASO therapeutic targeting SARS-CoV-2 · 2022
Not checked

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.